Accéder au contenu
Merck

1568007

USP

Progesterone

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

4-Pregnene-3,20-dione

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C21H30O2
Numéro CAS:
Poids moléculaire :
314.46
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1915950
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


grade

pharmaceutical primary standard

API family

progesterone

manufacturer/tradename

USP

mp

128-132 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

InChI key

RJKFOVLPORLFTN-LEKSSAKUSA-N

Gene Information

human ... PGR(5241)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Progesterone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Progesterone Compounded Vaginal Inserts
  • Progesterone Injection
  • Progesterone Intrauterine Contraceptive System

Biochem/physiol Actions

Induces maturation and secretory activity of the uterine endothelium; suppresses ovulation. Progesterone is implicated in the etiology of breast cancer.
Induit la maturation et l′activité secrétoire de l′endothélium utérin ; supprime l′ovulation.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Steroid hormone produced by the corpus luteum.
Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under Progesterone


pictograms

Health hazard

signalword

Danger

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



Xiaofei Sun et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2380-2389 (2014-01-29)
Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) is expressed in many organs, including female reproductive organs, and is a stem cell marker in the stomach and intestinal epithelium, hair follicles, and ovarian surface epithelium. Despite ongoing studies, the definitive physiological functions
Cathrin Brisken
Nature reviews. Cancer, 13(6), 385-396 (2013-05-25)
Understanding the biology of the breast and how ovarian hormones impinge on it is key to rational new approaches in breast cancer prevention and therapy. Because of the success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and aromatase
Eszter Papp et al.
The Journal of infectious diseases, 211(1), 10-18 (2014-07-18)
Protease inhibitor (PI)-based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestational-age (SGA) births. The mechanisms underlying these